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Abstract
Historically, antibiotic treatment guidelines have aimed to maximize treatment efficacy and minimize toxicity, but have not
considered the evolution of antibiotic resistance. Optimizing the duration and dosing of treatment to minimize the duration
of symptomatic infection and selection pressure for resistance simultaneously has the potential to extend the useful
therapeutic life of these valuable life-saving drugs without compromising the interests of individual patients. Here, using
mathematical models, we explore the theoretical basis for shorter durations of treatment courses, including a range of
ecological dynamics of bacteria that cause infections or colonize hosts as commensals. We find that immunity is an
important mediating factor in determining the need for long duration of treatment. When immunity to infection is
expected, shorter durations that reduce the selection for resistance without interfering with successful clinical outcome are
likely to be supported. Adjusting drug treatment strategies to account for the impact of the differences in the ecological
niche occupied by commensal flora relative to invasive bacteria could be effective in delaying the spread of bacterial
resistance.
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Introduction
Bacterial resistance to antibiotics has been growing and poses an
increasingly serious threat to modern medicine [1,2,3]. Reducing
unnecessary antibiotic use can lower the burden of resistant
pathogens, but it is difficult to balance this against the benefits of
antibiotics, real and perceived. Recent studies have shown that
strategies such as multiple first line treatments or drug combina-
tions can be effective in delaying resistance [4,5,6]. Optimized
dosing and duration of antibiotic regimens could play a similar
role in minimizing resistance without the need to deny treatment
to patients for whom therapy helps insure against low-probability,
high-consequence outcomes, such as mastoiditis in children with
acute otitis media. However, these approaches have received
relatively less attention. The relationships between drug dosing,
treatment duration, drug pharmacokinetics and pharmacodynam-
ics, and therapeutic efficacy that would inform decision-making
are only now beginning to be understood [7]. The benefits to the
individual, however, may be better evaluated by also considering
broader immunological, epidemiological and ecological conse-
quences of antibiotic use.
The optimal duration and dosing of antibiotic treatment is
influenced by the dynamics of infection and immunity. A drug
regimen must be given at a sufficiently high dose and sufficiently
long duration to clear an infection. Since dosing must be low
enough to avoid toxicity, the recommended drug dose is typically
set just below the maximally tolerated dose and, consequently, in
some cases, just slightly above the minimum concentration
required to clear infection [8]. However, as resistance increases,
so do the minimum inhibitory concentrations (MICs) and the
amount of drug required to achieve a cure. It has been suggested
that drug dosing that yields concentrations above the minimum
required for inhibitory effect of the most resistant bacteria
throughout the treatment would result in less selection for
resistance [7]. Immunity is a strong ally in this process, since a
strong immune response can significantly limit the need for long-
duration treatments, and indeed, there has been a tendency
towards shorter treatment regimen for some common acute
infections [9,10,11,12,13,14,15,16] in patients with intact primary
and secondary host defenses.
The propensity of pathogens to also colonize other parts of the
host without causing disease should also be relevant to the design
of the appropriate treatment profile. Most bacterial pathogens are
able to colonize the upper respiratory tract, the skin, the gut, or
other tissues without causing disease. When bacteria infect sterile
tissues, transmission is generally inefficient. For example, the
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tissue spaces and that cause septicemia are not shed and are
therefore not infectious, while the staphylococci colonizing the skin
of the same host are well positioned to so in a population through
skin-to-skin contact. The public health perspective would place
value in optimizing drug regimens for bacterial infections that lead
to treatment success in the patient but doing so in a way that
minimizes the risk of resistance in the ecological reservoir.
Pharmacodynamic and pharmacokinetic properties of many
antibiotics differ at the infection and colonization sites, making it
more difficult to select one regime that achieves both objectives.
Presently we lack the means to predict whether adjustments in the
delivered dose, and the impact of that adjustment on successful
therapy of the patient’s infection, alter the risk to the public health
related to the development of resistance in the colonizing and
potentially transmissible flora.
Here we evaluate optimal dosing by considering a broader
picture of the factors that influence the selection of antibiotic
resistance. Important differences among bacteria suggest that
ecological theory and mathematical models can help identify and
frame the relevant issues. To this end, we have explored simple
pharmacokinetic and pharmacodynamic (PK/PD) within-host
models to determine optimal antibiotic dosing strategies that
simultaneously minimize morbidity and selection for resistance.
The models are used to compare the outcome of treatment
regimes and classify pharmacodynamics across a broad range of
conditions that, unlike earlier studies, consider how the drug might
act differently on infecting and colonizing bacteria. These
simulations were used to provide a theoretical basis for shorter
dosing regimens, identify important parameters that dispropor-
tionately influence the optimal strategy, and establish the basis for
a broader agenda for designing drug treatment strategies to slow
resistance.
Methods
To describe a broad range of possible dynamics of host and
pathogen that may be clinically relevant, and to understand the
way those interactions are altered by the presence of a drug given
at varying effective concentrations, we use a model of bacterial
population dynamics based on one described by Austin and
Anderson [17]. The model considers competition between drug-
sensitive and drug-resistant bacteria with population sizes of S and
R, respectively. These populations are limited to some extent by an
immune response I. The model assumes that bacteria grow at the
rate l, but a fraction, m, of the sensitive bacteria become resistant
through mutations. Sensitive and resistant bacteria die at the rates
jS and jR, respectively, and jR.jS because of a biological cost of
resistance. Growth of both bacterial populations is limited by the
maximum population size K, and population sizes closer to the
maximum population size imply reduced growth rates. The
functions fR and fS describe the relation between antibiotic
concentration and antibiotic effect on bacteria–i.e., the pharma-
codynamics. The immune response grows in response to the
bacteria challenge: a is the maximum per capita proliferation rate,
b is the bacterial population that gives half the maximum rate, and
1/d is the average duration of the immune response. Killing of
bacteria by the immune response is assumed to occur in the same
manner regardless of resistance at a rate directly proportional to
the strength of the immune response with a killing rate constant c.
The dynamics are described by the following coupled ordinary
differential equations:
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Antibiotic Therapy, Resistance and Clinical Outcomes
In order to consider the best case for dosing to clear infection
while minimizing resistance, we assume there are no natural
constraints on pharmacokinetics and that drug concentrations are
maintained at a constant level throughout treatment. Given a
concentration c, the antibiotic effect on bacteria is described using
an Emax model [18,19,20,21,22,23],
fi c ðÞ ~Emax
c
czci
, i~R,S ð2Þ
where Emax is the maximum effect and ci is the drug required to
produce half of the maximum effect for strain i. With cR.cS,
resistant bacteria are not fully resistant to the drug but instead
require a higher drug concentration for clearance.
The effect of drug pressure on selection for resistance varies by
dosage and treatment duration, but also depends on the dynamics
of target and non-target bacterial flora. Each bacterial specie can
have different dynamics in each of the habitats it inhabits.
Therefore, the tissue concentration of antibiotics reached at the
infection site may not be equal to the concentration reached at the
colonization sites. We varied drug levels and their effects to
simulate selection on bacteria under a range of conditions that
could be encountered by bacteria under antibiotic drug exposure.
Concentrations were varied from below the MIC of the susceptible
strain to above the MIC of the resistant strain. With m=0 and the
interpretation that the MIC corresponds to the concentration that
just inhibits bacterial growth, the MIC can be expressed by
l{ji ðÞ ci=Emax{ l{ji ðÞ . Parameters for the simulations were
chosen to achieve a weak and strong drug action, defined by
Emaxvl{ji and Emaxwl{ji, respectively.
Although the terms ‘‘colonization’’ and ‘‘infection’’ are clinically
meaningful, they do not capture aspects of disease dynamics
important for understanding resistance. We have therefore used
four arbitrary but hopefully helpful definitions of infection
dynamics that are motivated by a formal stability analysis of the
mathematical model (see Text S1 for more details): unregulated,
regulated, opportunistic, and self-limiting bacterial dynamics.
Unregulated dynamics. The interaction between the
bacterial population and the host is insufficient to stimulate an
immune response and the resistant and sensitive bacteria settle to
equilibrium. This type of interaction could occur among bacteria
that use the body primarily as a commensal habitat [24]—e.g.
commensal staphylococcal flora of the skin. While those organisms
may interact with the specific cell surface of epithelial cells, without
an interruption of the epidermal layer, the organisms in this state
do not provoke an immune response. Other examples of this type
of dynamics could include a variety of potential pathogenic
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Helicobacter species, prior to causing invasive disease.
Regulated dynamics. Bacterial growth is followed by an
immune response and both the bacterial populations and the
immune response oscillate before settling to equilibrium.
Continuing on the example of staphylococci, should there be an
interruption of the epidermal layer, staphylococci numbers will
increase and an immune response will be generated. To the degree
that the epidermal layer is repaired, the organism burden will drop
back to the original levels after a burst of replication. To the
degree that the epidermal layer is not repaired, organism counts
may remain higher than baseline, ultimately achieving a new
equilibrium state. Clinical conditions ranging from trauma, to
underlying fungal infections to atopic dermatitis and eczema [25]
could all interrupt the intact skin layer and trigger this type of
dynamic. Another clinical example could include infection with
Mycobacteria tuberculosis, where the initial pulmonary exposure to the
organism results in mild, localized disease which is checked by the
immune system but results in an immunologic de ´tente, in which
the relatively dormant organism is now encased within a
granuloma, precluding continued replication but failing to fully
eradicate the threat.
Opportunistic dynamics. Bacteria arrive at a stable regulated
equilibrium under drug exposure, but as the initial immune response
develops, bacteria are driven down to very low densities that are
below a cutoff value of one organism defined for eradication (see
definition below) without drug exposure. Again, in the case of a skin
infection, drug exposure has reduced the burden of organisms, as
well as the cellular and immunotoxins generated by the
staphylococci, in the locally infected site, allowing the immune
response to return and maintain the bacterial count at levels even
below the original colonizing state. Within the respiratory tract a
similar dynamic may occur between Streptococci pneumoniae and
the local mucosal host defenses. Although S. pneumoniae can reside
within the respiratory tract without causing disease, should
symptomatic infection occur as a consequence of an increasing
burden of organisms, antibiotic intervention may drive down the
number of organisms to levels at or below that consistent with
eradication.
Self-limiting dynamics. Bacteria are driven down by the
immune response to an equilibrium density below the cutoff. In a
sense this is a specific outcome among the regulated dynamics in
which the organism burden is essentially eliminated. For example,
the invading staphylococci are destroyed by a combination of
primary and secondary immune responses, without antibiotic
intervention. In another clinical example, bacterial overgrowth
and invasion triggers an immune response in the middle ear
sufficient to reduce the bacterial burden to levels at or below the
equilibrium density, with or without symptoms.
Opportunistic and self-limiting dynamics differ in that, in the
case of opportunistic dynamics, re-exposure to bacteria in the
presence of a pre-existing, primed immune response could lead to
a stable regulated dynamic but with an equilibrium value above
the cutoff defined as ‘eradication’, while the self-limiting infection
will always result in the eradication of the organism. Population
densities of regulated or unregulated commensal dynamics tend to
be close to their population dynamic equilibrium at the time of
treatment, while opportunistic and self-limiting dynamics are
typically in the geometric growth phase of the infection when
treatment starts. The differences between these types of pathogen
dynamics and their simulations are illustrated in Figure 1.
For each of these types of bacterial dynamics, we analyze three
different outcomes; aggregated resistant bacterial load (defined as
the integral of R(t)), the aggregated fraction of resistance (defined
as the integral of R(t)/(R(t)+S(t))) and the time with symptoms
(defined as time with bacterial loads .10
7).
Cutoff Value
To obtain more realistic results from our simulations, we have
defined a cutoff value of one bacterium as the minimum value
required for survival of a bacterial population. Once the last
bacterium has died, the population has been eradicated.
Results
Selection for antibiotic resistance and clinical outcomes differ,
depending on the ecological dynamics of the pathogen in relation
to dosing and duration of treatment (Fig. 2).
Optimizing treatment for regulated or unregulated
pathogen dynamics
If pathogens, whether regulated or unregulated by the immune
response give rise to symptoms, antibiotics must be relied on for
elimination of symptoms, and high drug doses for long durations
will be required (right panel, Fig. 2). Clinical examples include
tuberculosis, acne and Helicobacter pylori. These chronic or
recurrent infections differ in terms of severity of symptoms but
require prolonged or repeated antibiotic therapy/prophylaxis. If
resistant subpopulations are initially present (as is the case in our
simulations) or arise through mutation or genetic transfers during
the course of treatment, the frequency of resistance will correlate
with the time that a drug concentration is maintained between the
MICs of the susceptible and resistant strains (left panel, Fig. 2),
consistent with findings from in vitro pharmaco-kinetic studies
[26,27]. Although mutants with MICs between the sensitive and
resistant strains play a major role in the evolution of resistance, we
also show that the frequency of resistance increases with duration
of antibiotic treatment for the other dosing strategies. We arrive at
similar qualitative conclusions regardless of whether the outcome
measures are in terms of aggregated number or aggregated
fraction of bacteria (figures not shown).
While resistance evolution of regulated or unregulated infections
is a significant issue for some infections, the impact of antibiotic
treatment on commensal bacteria is often overlooked. Resistance
in commensals is clinically important, because each episode of
treatment places selection pressure in favor of resistance in both
the infection and the commensal sites. Moreover, for a given level
of drug concentration, selection is more extensive in commensals
because of the lack of a strongly limiting immune response.
Regardless of pathogen dynamics, it is unlikely that antibiotic
treatment can successfully clear colonization of the host due to the
large numbers of organisms in the commensal flora. Antibiotic
resistant bacteria are more likely enriched in the commensal flora
of patients with high antibiotic usage [28].
Although large, stable commensal bacterial populations are
driven toward fixation of resistance under antibiotic pressure, the
frequency of resistant organisms declines to a mutation-selection
balance when the drug pressure is relaxed, by assumption, as a
result of the fitness cost related to genetic reassortment (see Text
S1). This balance may be further complicated by the presence of
factors not considered here, such as compensatory mutations,
which reduce the biological cost of resistance [29].
Optimizing treatment for self-limiting or opportunistic
pathogen dynamics
Self-limiting pathogen dynamics differ from regulated or
unregulated dynamics in several aspects. First, as the name
‘‘One-Size-Fits-All’’?
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and the time with symptoms is substantially shorter relative to
deep tissue infections, with or without antibiotics. Important
clinical examples include some of the most common infections,
acute otitis media (AOM) and acute sinusitis, for which empirical
studies have shown that no treatment or a short treatment of three
days is efficient for curing the infection [11,12,15,16,30,31,32].
As is seen in Figure 1 (compare opportunistic dynamics with
and without drug), drugs can change the dynamic outcomes.
Opportunistic infections may resemble self-limiting infections in
their dynamics without drug exposure, but drugs can change the
dynamics to end up at a stable regulated equilibrium. The
resulting chronic colonization or infection could have long-term
consequences on the patient’s health. These dynamics could
Figure 1. Simulation results showing the bacterial counts for the four different dynamics, assuming two different drug
concentrations (c=0 black, and c=10 grey). Unregulated dynamics: No immune response is stimulated in the case of unregulated dynamics
and the resistant and sensitive bacteria settle to equilibrium. Regulated dynamics: both bacterial populations and the immune response oscillate
before settling to equilibrium. Opportunistic dynamics: bacteria end up at a stable regulated equilibrium under drug exposure, but are driven down
to very low densities that are below the cutoff value defined for eradication without drug exposure. Self-limiting dynamics: bacteria are driven down
to an equilibrium density that is below the cutoff value by the immune response.
doi:10.1371/journal.pone.0029838.g001
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occurs more often in children treated with antibiotics than those
untreated [33].
Second, for both self-limiting and opportunistic infections the
selection for resistance (in aggregate numbers of resistant bacteria)
is most extensive for intermediate dosing strategies near the MIC
for intermediate durations (see Fig. 2). The results presented
assume a weak action by the drug. The dynamic differ slightly
when the action by the drug is strong (see Fig. 3), but our
conclusions are robust to these variations.
Thus, for infections caused by organisms which are commensal
in their normal habitat, the best strategy would be a short and
aggressive treatment early in an infection to keep bacteria
populations low until the immune system can finish the job—
because this strategy will minimize the selection for resistance
among the commensals at the same time as minimizing selection
in the infection site. The tradeoff of choosing the strategy that
minimizes resistance is that the time with symptoms becomes
longer with shorter durations of antibiotics.
Discussion
Recent developments in the field of antibiotic pharmacody-
namics have led to a better knowledge of the optimal dosage
strategies to obtain maximal eradication of the infecting pathogen
[34,35]. Further, optimizing the duration and dosing of treatment
to reduce the likelihood of resistance for a given level of antibiotic
use, however, remains a challenge. Resistance to dozens of
antibiotics has evolved in hundreds of bacterial species, but the
relationships between dosage regimens, pharmacokinetics and
therapeutic efficacy in the context of bacterial resistance are only
now beginning to be understood [7]. The public health response to
various aspects of the resistance problem has largely focused on a
single solution—the reduction of antibiotic overuse. A more
holistic approach may be to build up a functional taxonomy, a
classification of bacterial pathogens that are functionally similar for
resistance evolution. A functional taxonomy would consider
pathogen ecology, the dynamics of immunity along with other
issues that are important determinants of transmission and of
population structure. Those other important concerns may include
the typical population sizes of colonizing bacteria, their intrinsic
resistance to antibiotics, their tendency to accumulate resistance
genes, and species-specific cross-resistance to dominant antibiotics.
Our research particularly emphasizes the public health
importance of understanding the dynamics of bacterial pathogens
in their dominant ecological reservoir, and pharmacodynamic and
pharmacokinetic parameters operating in those tissues, as an
important complement to concerns about optimizing treatment for
bacterial infections.
In this paper, we show that 1) all antibiotic use—even under a
‘‘perfect’’ dosing strategy—exerts selection for resistance, and 2)
for most infections the optimal dosing strategy for clinical
treatment may not be optimal for preventing the spread of
resistance, likely a consequence of those treatment regimens may
not being focused on the dynamics of bacterial populations. The
general rule suggested by our studies is that shorter duration of
treatments is usually, but not always, optimal. More comprehen-
sive guidelines that consider the important differences among
bacteria in their ecological dynamics, as well as in the diversity of
ecological dynamics for the same bacteria in different habitats in
the body could contribute to dramatically reduce the volume of
antibiotics consumed and selection for resistance.
An example is the treatment of AOM—the second most
common infection among children after the common cold, and the
single most important reason for antibiotic prescriptions in the
United States [36]. Here, no treatment or a short three-day course
with antibiotic treatment has been shown to be no less effective
than ten days with antibiotics [12,30,31]. The motivation for the
trend and steady progress in designing shorter drug regimens have
been based on clinicians’ experience rather than on systematic
evaluation of the trade-off between treatment success and
resistance, and yet, many physicians continue to recommend that
patients complete the full 10 day course of antibiotic treatment
[37,38], thereby potentially accelerating the rate with which
resistance evolves and spreads from other bacterial populations. A
guideline change toward shorter treatment durations with
antibiotics would not only prevent resistance among individuals
receiving antibiotics for self-limiting infections, but also among the
large number of patients receiving antibiotics for nonbacterial
infections [39].
For infections that cannot be handled by the immune system
alone, i.e. for which high concentrations of antibiotics for long
durations are required, it is important to consider the functional
taxonomy of the drugs used. The mode of administering the
antibiotic is important because it affects the concentrations of the
drug in other parts of the body; antibiotics typically reach much
higher concentrations in the gut if given orally rather than
intravenously [40]. For instance, there is evidence suggesting that
the rise of vancomycin-resistant enterococci in the United States
during the 1980s could have been driven by the use of oral
vancomycin for C. difficile [41]. In Europe, where vancomycin was
mostly used intravenously, vancomycin concentrations and
selection for resistance in gut commensals would be expected to
be much lower, and vancomycin-resistant enterococci are much
less frequent. Tuberculosis treatment does not impose an increased
selection for resistance, despite extensive drug regimes, because
Mycobacterium tuberculosis does not form a part of the commensal
flora, and because the two key agents (izoniazid and ethambutol)
Figure 2. The outcomes of different dosing strategies on the aggregate number of resistant bacteria (left panel) and time with
symptoms (bacterial loads .10
7, right panel) are contrasted for regulated, self-limiting, and opportunistic bacterial populations.
The antibiotic concentration is assumed to be constant throughout the treatment at the concentration displayed by the y-axis for a time displayed by
the x-axis. The pink color indicates the area with the strongest selection for resistance and the longest durations with symptoms. Resistance increases
with longer durations of antibiotics for regulated commensal. For opportunistic and self-limiting dynamics, the selection for resistance is most intense
for intermediate durations of antibiotics. The time with symptoms decreases with increased durations and concentrations of antibiotics for all types
of bacterial dynamics. The time with symptoms is relatively short for opportunistic and self-limiting dynamics compared to that of regulated
commensal dynamics. This illustrates the importance of the immune system for the clearance of bacterial populations. Simulation results for
unregulated dynamics (not displayed) are similar to that of regulated dynamics but selection for resistance is somewhat stronger and time with
symptoms somewhat longer. Parameters used to achieve regulated commensal dynamics are Emax=1,a=0.2, K=10
15, l=1.8, c50R=13.1, c50S=1.3,
c=50, b=10
6, d=50, m=10
28, jR=0.2, and jS=0.1. For unregulated commensal dynamics and opportunistic infection dynamics, d=0.05, and for
self-limiting infection dynamics, d=5? 10
28. A small subpopulation of bacteria is resistant at start. The initial value for the immune response is zero
for the unregulated commensal dynamics and is close to the equilibrium (?0) for other cases. Antibiotic concentration is kept fixed at the
concentration displayed by the y-axis for a time displayed by the x-axis. All parameters are given in arbitrary units.
doi:10.1371/journal.pone.0029838.g002
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teria, which are not a part of the commensal flora. In contrast, for
the treatment of acne with broad-spectrum antibiotics (minocy-
cline), sometimes for a year or more [42], our results suggest a
significant selection pressure on the commensal flora. By leaving
the gut flora, upper respiratory flora, and much of the skin flora
unexposed, topical usage of antibiotics could be a solution. It has,
however, long been discouraged and amounts to only 1% of
systemic use [39].
Since populations of commensal flora can be extensive, resistant
bacteria generated by otherwise rare mutations or genetic
exchange events are likely to exist and comprise some part of
the existing flora at the time of antibiotic treatment [43]. Resistant
commensal bacteria are therefore more likely to persist and cause
resistant infections when they spread to other hosts. Even if they
do not cause infection, commensal bacteria can transfer genetic
material coding for resistance to other, more pathogenic bacteria.
It follows that the value of drug optimization is related to the full
spectrum of drug pharmacokinetics and pharmacodynamics
throughout the body, both in terms of the delivery mode and
the organisms it targets. Optimization of treatment in the primary
ecological reservoir for transmission is both the best measure of
collateral damage in transmission models and the most important
consideration for public health. Our results emphasize the need to
reexamine topical, intravenous, or focal delivery of antibiotics for
other drug and organism combinations.
Caveats and Limitations
Like all mathematical models of biological systems, the models
analyzed here involve some assumptions and simplifications.
Mutations in the model are generated through a one-step process.
Genetic transfers typically result in higher levels of resistance, but
are unlikely to occur in self-limiting infections unless there is a
coinfection; the first documented case of infection caused by
vancomycin-resistant S. aureus is one important example [39].
Allowing for mutations to high-level resistance at the colonization
site increases the time span in which there is extensive selection for
resistance, but does not alter our conclusions.
We assumed drug concentration were maintained at a constant
level throughout treatment—an assumption which is unnatural for
most situations other than for intravenous treatment [18]. For oral
and intramuscular administration, the concentrations of antibiotics
will be in a continuous state of flux, and the dynamics could be
further confounded by factors such as non-compliance. As result,
the effect of periodic waning of antibiotic concentrations below the
effective MICs are not considered in our analysis, but instead
constant concentrations either below or above the effective MICs
are considered. Accounting for periodic waning of antibiotic
concentrations to below the effective MICs will affect the intensity
of the selection for resistance and the time scale for the dynamics
and should therefore be considered in future analyses for antibiotic
and pathogen specific guidelines.
The MIC was used as a single pharmacodynamic parameter in
the model. The pharmacodynamic function captures the effect of
an antibiotic over a wide range of antibiotic concentrations and as
a consequence of differences in the shape of these pharmacody-
namic functions, antibiotics with the same MICs and pharmaco-
kinetics may differ profoundly in their microbiological efficacy
[23]. This assumption may have to be relaxed for future
predictions in the development of antibiotic treatment protocols
for specific drug and organism combinations.
An important aspect of our study was that we explicitly
considered the different dynamics of drugs and bacteria that could
occur at the infection site and in other habitats, taking into account
the effects of immune response on the emergence of and selection
for resistance. Bacteria populations in different habitats in a body
are not expected to have strong direct interactions, so the
population responses would be different and largely independent.
Because of the many interdependent mechanisms, such as different
cell types and cytokines involved in the immune responses to
bacterial infections, experiments to measure the contribution of
various components have been difficult, and precise knowledge
about these processes is still lacking [44]. The focus of this study,
however, was not prediction of resistance emergence for a specific
infection or species of the microflora, but rather a conceptual
framework for addressing questions about the impact of
considering both the infection site and the commensal site in the
optimization of antibiotic drug dosing regimens to prevent
resistance.
In the model, the immune response depends on the total
bacterial population. There is, however, evidence that some
pathogens may escape the effects of an antibiotic by moving from
the extracellular to the intracellular space. In contrast to our
assumption, resistance to an antibiotic would then be correlated
with increased resistance to the immune response [45,46]. The
evidence for this phenomena is still emerging and further
investigation is needed. Were this observation to become
established, however, the degree of resistance prior to treatment
could affect the overall immune response.
There may be other important clinical outcomes to consider in
the evaluation of dosing strategies. Some studies for instance have
reported an increase in the number of complications from
countries with lower rates of antibiotic prescribing for AOM
[47]. The incidence is low, however, and the risk of more serious
sequelae has to be weighed against the risk and consequences of a
strategy that generates more-resistant organisms.
Figure 3. The outcomes of different dosing strategies on the aggregate number of resistant bacteria (left panel) and time with
symptoms (bacterial loads .10
7, right panel) are contrasted for regulated, self-limiting, and opportunistic bacterial populations.
The antibiotic concentration is assumed to be constant throughout the treatment at the concentration displayed by the y-axis for a time displayed by
the x-axis. The pink color indicates the area with the strongest selection for resistance and the longest durations with symptoms. Resistance increases
with longer durations of antibiotics for regulated commensal dynamics. For opportunistic and self-limiting dynamics, the selection for resistancei s
most intense for intermediate durations of antibiotics. The time with symptoms decreases with increased durations and concentrations of antibiotics
for all four types of bacterial dynamics. The time with symptoms is relatively short for opportunistic and self-limiting dynamics compared to that of
regulated commensal dynamics. This illustrates the importance of the immune system for the clearance of bacterial populations. Simulation results
for unregulated dynamics (not displayed) are similar to that of regulated dynamics but selection for resistance is somewhat stronger and time with
symptoms somewhat longer. The Emax parameter was set to 3 to contrast the results for a situation with strong action by drugs. The other parameters
used to achieve regulated commensal dynamics are a=0.2, K=10
15, l=1.8, c50R=13.1, c50S=1.3, c=50, b=10
6, d=50, m=10
28, jR=0.2, and jS=0.1.
For unregulated commensal dynamics and opportunistic infection dynamics, d=0.05, and for self-limiting infection dynamics, d=5?10
28. A small
subpopulation of bacteria is resistant at start. The initial value for the immune response is zero for the unregulated commensal dynamics and has a
value close to the equilibrium (?0) for the other cases. All parameters are given in arbitrary units. Lower and upper dashed lines represent the MICs of
sensitive and resistant bacteria, respectively.
doi:10.1371/journal.pone.0029838.g003
‘‘One-Size-Fits-All’’?
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29838Lastly, this study only captured one of the two overlapping
problems related to resistance: the emergence and selection of
resistant strains within the host. For many infections, primary
resistance caused by the spread of resistant strains within a
population is the most significant problem [48] and it remains
important for future studies to evaluate whether the gain of
treating a patient outweighs the risk of resistance in the population.
Summary and Conclusions
Existing antibiotic treatment guidelines do not consider 1)
important differences in the ecological dynamics among different
bacterial species or 2) the diversity of ecological dynamics within
the same bacterial species in different habitats in the body. Our
results challenge the conventional clinical wisdom that long
durations of antibiotic therapy are appropriate for common
infections regardless of whether or not they are self-limiting, and
regardless of the potential for selection for resistance in the
commensal flora. In conclusion, one-size-fits-all dosing regimens
do not fit all combinations of organisms and antibiotics,
demanding a need to broaden the principles employed in selection
of dosing regimens for both existing and future antibiotics to
include not only successful treatment of the underlying infection
but doing so in a manner that minimizes the pressure to select for
increasingly more antibiotic resistant pathogens.
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